Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday, Zacks reports.
Several other research analysts have also recently commented on the stock. Nordea Equity Research cut shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, October 22nd. Pareto Securities upgraded shares of Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a report on Tuesday, October 27th. Finally, HC Wainwright restated a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Swedish Orphan Biovitrum currently has an average rating of “Moderate Buy”.
Check Out Our Latest Report on BIOVF
Swedish Orphan Biovitrum Stock Performance
Shares of BIOVF opened at $51.05 on Thursday. The business’s 50-day moving average price is $46.40 and its 200 day moving average price is $45.13. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $18.17 billion, a P/E ratio of 25.40 and a beta of 0.48. Swedish Orphan Biovitrum has a 1-year low of $35.25 and a 1-year high of $51.05.
Swedish Orphan Biovitrum Company Profile
Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.
Featured Articles
- Five stocks we like better than Swedish Orphan Biovitrum
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.
